下一個疫苗？2010∼2020年的產品線上之HIV、瘧疾、狂犬病、MRSA以及其他30種以上的疫苗目標 是由出版商Kalorama Information在2010年02月所出版的。
這份英文市場調查報告書包含220 pages 價格從美金4200起跳。
本報告，彙整了至2020年各種疫苗的開發動向與收益預測，並加上市場區塊別之全球的收益、市場參與企業的檔案資料等，由下列摘要形式闡述。
第1章 報告摘要
第2章 疫苗簡介
- 簡歷：疫苗的發展
- 免疫反應
- 作用機制
- 疫苗的種類
- 疫苗認證程序
- 驅動疫苗市場的趨勢
第3章 新興疫苗
- 簡介
- 疾病別之新興疫苗
- 成癮
- 過敏
- 阿茲海默症
- 炭疽病
- 氣喘
- 衣原體 其他
第4章 新興疫苗市場之預測
第5章 課題與趨勢
第6章 企業檔案資料
- Acambis plc
- ACE BioSciences
- AFFiRiS
- ALK-Abello A/S
- Allergy Therapeutics
- Bavarian Nordic A/S
- Baxter Healthcare
- Celldex Therapeutics
- Crucell
- Cytos Biotechnology
- GlaxoSmithKline
- Hawaii Biotech
- Intercell
- Medimmune
- Merck & Co. Inc
- Mymetics
- Nabi Biopharmaceuticals
- Novartis
- Opexa Therapeutics
- Paladin Labs
- Sanofi Pasteur
附錄
企業指南
圖表
Abstract
The global market for human vaccines has experienced strong growth in the past
few years, and R&D departments at many pharmaceutical companies are working on
new prophylactics, some of which may see near-term marketing. What illnesses
may see a vaccine option in the coming years? Which vaccines will have the
most successful business model? Who are the major companies in this market,
and possible new entrants? What can current vaccine success stories tell us
about the future of the vaccine market? This Kalorama Information report
What' s Next in Vaccines? examines and estimates the market for vaccines that
have yet to be launched, including the following target areas:
- Addiction
- Allergy
- Alzheimer' s Disease
- Anthrax
- Asthma
- Campylobacter Infection
- Chlamydia
- Croup
- Dengue Fever
- Diabetes
- Ebola
- Epstein-Barr Virus
- Enterotoxigenic Escherichia coli
- Helicobacter Pylori
- Hepatitis
- Herpesvirus
- Hookworm
- Hypertension
- HIV/AIDS
- Leishmaniasis
- Malaria
- MRSA Infection
- Multiple Sclerosis
- Obesity
- Parainfluenza Virus Type 3
- Parkinson' s Disease
- Plague
- Respiratory Syncytial Virus
- Ross River Virus
- Shigellosis
- Smoking
- Stroke
- Tuberculosis
- West Nile Virus
Some of these vaccines may see success; some could be the blockbusters of the
future. For marketers and industry watchers a knowledge of all of the
potential vaccines will be important to understand how pharma is seeking to
renew bottom line with aggressive prophylactic strategies, and who the winners
and losers in the near future may be. Alison Sahoo has looked at the vaccine
market three times in as many years for Kalorama Information, and in this
report applies a knowledge of what companies have done in the past to
potential efforts.
There are a number of trends that will impact the industry that market
watchers will want to know about, and Kalorama Information has covered these
trends; including: New Vaccine Technologies, DNA Vaccination, Innovative
Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The
report also discusses vaccine manufacturing methods and the approval process.
In addition, the report focuses on the emerging vaccine activities of the following companies:
- Acambis plc
- ACE BioSciences
- AFFiRiS
- ALK-Abello A/S
- Allergy Therapeutics
- Bavarian Nordic A/S
- Baxter Healthcare
- Celldex Therapeutics
- Crucell
- Cytos Biotechnology Financial GlaxoSmithKline
- Hawaii Biotech
- Intercell
- Medimmune
- Merck & Co. Inc
- Mymetics
- Nabi Biopharmaceuticals
- Novartis
- Opexa Therapeutics
- Paladin Labs
- Sanofi Pasteur
This report provides forecasted revenues for products in development out to
2020. The report does not does not cover indication expansions of existing
vaccine products, nor does it cover vaccines for which products currently
exist and are widely available, but may need improvement. Development of
vaccines that incorporate new production methods (such as the migration of
chicken eggs to mammal, yeast or other cells) is also excluded. Cancer
vaccines are excluded as Kalorama has an entire report on this topic.
Sales estimates for each market segment represent global revenues and are
expressed in current dollars. Information for this report was gathered from a
wide variety of published sources including company reports and filings,
government documents, legal filings, trade journals, newspapers and business
press, analysts' reports and other sources.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope and Methodology
- Overview
- Emerging Vaccines and Forecasts
- The Global Market for Emerging Vaccines
CHAPTER TWO: INTRODUCTION TO VACCINES
- A Brief History: The Development of Vaccines
- The Immune Response
- Mechanism of Action
- Types of Vaccines
- Attenuated (Weakened) Live Viruses
- Killed (Inactivated) Viruses
- Toxoid Vaccines
- Genetically Engineered/Modified Vaccines
- Bacteria-Based Vaccines
- Subunit Vaccines
- Conjugate Vaccines
- DNA Vaccination
- Vaccine Approval Process
- Trends Driving the Vaccines Market
CHAPTER THREE: EMERGING VACCINES
- Introduction
- Emerging Vaccines by Disease Area
- Addiction
- Allergy
- Alzheimer' s Disease
- Anthrax
- Asthma
- Campylobacter Infection
- Chlamydia
- Croup
- Dengue Fever
- Diabetes
- Ebola
- Epstein-Barr Virus
- Enterotoxigenic Escherichia coli
- Heart Attack
- Helicobacter Pylori
- Hepatitis
- Herpesvirus
- Hookworm
- Hypertension
- HIV/AIDS
- Leishmaniasis
- Malaria
- MRSA Infection
- Multiple Sclerosis
- Obesity
- Parainfluenza Virus Type 3
- Parkinson' s Disease
- Plague
- Respiratory Syncytial Virus
- Ross River Virus
- Shigellosis
- Stroke
- Tuberculosis
- West Nile Virus
CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST
- Global Market for Emerging Vaccines
- Emerging Vaccines Market Segment Forecasts
- Addiction
- Allergies
- Alzheimer' s Disease
- Anthrax
- Asthma
- Campylobacter Infection
- Chlamydia
- Croup
- Dengue Fever
- Diabetes
- Ebola
- EBV Infection
- ETEC Infection
- Heart Attack
- H. Pylori Infection
- Hepatitis C and E
- Herpesvirus Infection
- Hookworm
- Hypertension
- HIV/AIDS
- Leishmaniasis
- Malaria
- MRSA Infection
- Multiple Sclerosis
- Obesity
- PIV-3 Infection
- Parkinson' s Disease
- Plague
- RSV Infection
- Ross River Virus Infection
- Shigellosis
- Stroke
- Tuberculosis
- West Nile Virus
CHAPTER FIVE: ISSUES AND TRENDS
- New Vaccine Technologies
- DNA Vaccination
- Innovative Delivery Systems
- Edible Vaccines
- Mucosal Delivery
- Intranasal Delivery
- Vaccine Patches
- Funding Shortfalls
CHAPTER SIX: COMPANY PROFILES
- Acambis plc
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- ACE BioSciences
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- AFFiRiS
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- ALK-Abello A/S
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Allergy Therapeutics
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Bavarian Nordic A/S
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Baxter Healthcare
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Celldex Therapeutics
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Crucell
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Cytos Biotechnology
- History and Lines of Business
- Emerging Vaccine Activities
- Financial
- GlaxoSmithKline
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Hawaii Biotech
- History and Lines of Business
- Emerging Vaccine Products
- Financial Information
- Intercell
- History and Lines of Business
- Emerging Vaccine Products
- Financial Information
- Medimmune
- History and Lines of Business
- Emerging Vaccine Products
- Financial Information
- Merck & Co. Inc.
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Mymetics
- History and Lines of Business
- Emerging Vaccine Products
- Financial Information
- Nabi Biopharmaceuticals
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Novartis
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Opexa Therapeutics
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Paladin Labs
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
- Sanofi Pasteur
- History and Lines of Business
- Emerging Vaccine Activities
- Financial Information
Appendix
Company Directory
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Status of Emerging Vaccines by Disease
CHAPTER TWO: INTRODUCTION TO VACCINES
- Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the
20th Century vs 2008
- Table 2-2: Vaccine-Preventable Diseases, December 2009
- Table 2-3: VAERS Table of Reportable Events Following Vaccination
CHAPTER THREE: EMERGING VACCINES
- Figure 3-1: Global Prevalence of Conditions Addressed by Emerging Vaccines
- Figure 3-2: Comparative Mortality, Symptom Severity and Treatment
Availability for Conditions Addressed by Emerging Vaccines
- Table 3-1: Emerging Vaccines by Disease and Stage of Testing
- Figure 3-3: Comparative Severity Ranking of Addiction
- Figure 3-4: Comparative Severity Ranking of Allergy
- Figure 3-5: Comparative Severity Ranking of Alzheimer' s Disease
- Figure 3-6: Comparative Severity Ranking of Anthrax
- Figure 3-7: Comparative Severity Ranking of Asthma
- Figure 3-8: Comparative Severity Ranking of Campylobacter Infection
- Figure 3-9: Comparative Severity Ranking of Chlamydia
- Figure 3-10: Comparative Severity Ranking of Croup
- Figure 3-10: Comparative Severity Ranking of Dengue Fever
- Figure 3-12: Comparative Severity Ranking of Diabetes
- Figure 3-13: Comparative Severity Ranking of Ebola
- Figure 3-14: Comparative Severity Ranking of EBV
- Figure 3-15: Comparative Severity Ranking of ETEC
- Figure 3-16: Comparative Severity Ranking of Heart Attack
- Figure 3-17: Comparative Severity Ranking of H. Pylori Infection
- Figure 3-10: Comparative Severity Ranking of Hepatitis C and E
- Figure 3-19: Comparative Severity Ranking of Herpesvirus Infection
- Figure 3-20: Comparative Severity Ranking of Hookworm
- Figure 3-21: Comparative Severity Ranking of Hypertension
- Figure 3-10: Comparative Severity Ranking of HIV/AIDS
- Figure 3-23: Comparative Severity Ranking of Leishmaniasis
- Figure 3-24: Comparative Severity Ranking of Malaria
- Figure 3-25: Comparative Severity Ranking of MRSA Infection
- Figure 3-26: Comparative Severity Ranking of Multiple Sclerosis
- Figure 3-27: Comparative Severity Ranking of Obesity
- Figure 3-28: Comparative Severity Ranking of PIV-3 Infection
- Figure 3-29: Comparative Severity Ranking of Parkinson' s Disease
- Figure 3-30: Comparative Severity Ranking of Plague
- Figure 3-31: Comparative Severity Ranking of RSV Infection
- Figure 3-32: Comparative Severity Ranking of Ross River Virus Infection
- Figure 3-33: Comparative Severity Ranking of Shigellosis
- Figure 3-34: Comparative Severity Ranking of Stroke
- Figure 3-35: Comparative Severity Ranking of Tuberculosis
- Figure 3-36: Comparative Severity Ranking of West Nile Virus Infection
CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST
- Table 4-1: World Market for Emerging Vaccines by Type, 2009-2020
- Table 4-2: World Market for Emerging Vaccines by Type, 2009-2020
- Table 4-3: World Addiction Vaccine Market 2009-2020
- Table 4-4: World Allergy Vaccine Market 2009-2020
- Table 4-5: World Alzheimer' s Disease Vaccine Market 2009-2020
- Table 4-6: World Anthrax Vaccine Market 2009-2020
- Table 4-7: World Asthma Vaccine Market 2009-2020
- Table 4-8: World Campylobacter Infection Vaccine Market 2009-2020
- Table 4-9: World Chlamydia Vaccine Market 2009-2020
- Table 4-10: World Croup Vaccine Market 2009-2020
- Table 4-11: World Dengue Fever Vaccine Market 2009-2020
- Table 4-12: World Diabetes Vaccine Market 2009-2020
- Table 4-13: World Ebola Vaccine Market 2009-2020
- Table 4-14: World EBVVaccine Market 2009-2020
- Table 4-15: World ETECVaccine Market 2009-2020
- Table 4-16: World Heart Attack Vaccine Market 2009-2020
- Table 4-17: World H. Pylori Vaccine Market 2009-2020
- Table 4-18: World Hepatitis C and E Vaccine Market 2009-2020
- Table 4-19: World Herpesvirus Vaccine Market 2009-2020
- Table 4-20: World Hookworm Vaccine Market 2009-2020
- Table 4-21: World Hypertension Vaccine Market 2009-2020
- Table 4-22: World HIV/AIDS Vaccine Market 2009-2020
- Table 4-23: World Leishmaniasis Vaccine Market 2009-2020
- Table 4-24: World Malaria Vaccine Market 2009-2020
- Table 4-25: World MRSA Vaccine Market 2009-2020
- Table 4-26: World Multiple Sclerosis Vaccine Market 2009-2020
- Table 4-27: World Obesity Vaccine Market 2009-2020
- Table 4-28: World PIV-3 Vaccine Market 2009-2020
- Table 4-29: World Parkinson' s Disease Vaccine Market 2009-2020
- Table 4-30: World Plague Vaccine Market 2009-2020
- Table 4-31: World RSV Vaccine Market 2009-2020
- Table 4-32: World Ross River Virus Vaccine Market 2009-2020
- Table 4-33: World Shigellosis Vaccine Market 2009-2020
- Table 4-34: World Stroke Vaccine Market 2009-2020
- Table 4-35: World Tuberculosis Vaccine Market 2009-2020
- Table 4-36: World West Nile Virus Vaccine Market 2009-2020
